|
T.GUD
|
Yes, that's the last I've seen about it as well. CapIQ doesn't...
|
|
T.GUD
|
Interesting! In the short-term, our results and financial situation will be...
|
|
T.GUD
|
Good to hear from you! You have a vision for something that I cannot comment...
|
|
T.GUD
|
While it's difficult to say which products are going to be launched in...
|
|
T.GUD
|
Just to keep track of this... In the February 2024 presentation, the peak...
|
|
T.GUD
|
Yes... we'll see how it goes. Always hard to predict price movements. It...
|
|
T.GUD
|
A few promotions / title changes within the Executives at Knight. Monica...
|
|
T.GUD
|
We will still see growth from the current portfolio (plus the couple of...
|
|
T.GUD
|
The Ardelyx drug is now doing about a million per year in sales for us. The...
|
|
T.GUD
|
Potential yearly combined sales went from $50M-$75M to $70-$100M.
|
|
T.GUD
|
During the past three months, GUD has bought back around 2.4 million shares...
|
|
T.GUD
|
As we discussed earlier, mr. Martens was absent from the previous earnings...
|
|
T.GUD
|
1.37 million shares (around $6 million) cancelled in September. That's...
|
|
T.GUD
|
Here you go: https://knighttx.com/Investors-Content/Presentation_Fact_Sheets...
|
|
T.GUD
|
Interesting bit of information in the quarterly report. Perhaps it's just...
|
|
T.GUD
|
Yes, it seems like there was a real possibility for something to happen with...
|
|
T.GUD
|
They have indeed put a lot of capital to use. $370M = GBT $180M = Exelon...
|
|
T.GUD
|
There were three people on the call: Samira, Amal and Arvind, as per Samira...
|
|
T.GUD
|
I would also agree that it was a mixed bag of results. Revenue growth but...
|
|
T.GUD
|
Updated Outlook: Revenue: $300-$320M to $310-$330M Adjusted EBITDA: 14-15...
|